Overview Dividends

(CLX) The Clorox - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1890541097

Disinfectants, Bleach, Litter, Dressings, Filtration

CLX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 50.65%
EPS Trend (3Y Correlation): 55.9%

CLX Revenue

Revenue Growth (3Y CAGR): 4.96%
Revenue Trend (3Y Correlation): 6.0%

Description: CLX The Clorox October 30, 2025

The Clorox Company (NYSE: CLX) manufactures and markets a broad portfolio of consumer and professional products across four segments: Health & Wellness (cleaning, disinfecting, bleach, and professional food-service items), Household (cat litter, Glad bags, Kingsford grilling supplies), Lifestyle (Hidden Valley dressings, Brita water-filtration, Burt’s Bees personal-care) and International (a mix of the same brands plus vitamins and supplements). Its products reach shoppers via mass retailers, grocery chains, warehouse clubs, dollar stores, hardware outlets, drug and pet stores, military channels, third-party and owned e-commerce sites, and a direct sales force.

In FY 2023 Clorox generated roughly $7.8 billion in net sales, with an operating margin of about 15 % and a dividend yield near 2.5 %. The Health & Wellness segment contributed the largest share of revenue, driven by sustained demand for disinfecting solutions post-COVID-19, while the Lifestyle segment showed double-digit growth from premium-priced natural personal-care and water-filtration products.

Key economic drivers for CLX include inflationary pressure on raw-material costs (e.g., sodium hypochlorite and plastics), modest pricing power in the defensive household-products sector, and a consumer shift toward sustainable and “green” brands-trends that have historically supported modest revenue resilience. For a deeper quantitative assessment, you may find the ValueRay platform’s sector-adjusted valuation models useful.

CLX Stock Overview

Market Cap in USD	13,695m
Sub-Industry	Household Products
IPO / Inception	1983-03-21

CLX Stock Ratings

Growth Rating	-58.0%
Fundamental	74.5%
Dividend Rating	52.2%
Return 12m vs S&P 500	-40.0%
Analyst Rating	3.05 of 5

CLX Dividends

Dividend Yield 12m	4.58%
Yield on Cost 5y	2.96%
Annual Growth 5y	2.76%
Payout Consistency	64.2%
Payout Ratio	83.8%

CLX Growth Ratios

Growth Correlation 3m	-55.6%
Growth Correlation 12m	-95.6%
Growth Correlation 5y	-40.3%
CAGR 5y	-5.76%
CAGR/Max DD 3y (Calmar Ratio)	-0.16
CAGR/Mean DD 3y (Pain Ratio)	-0.43
Sharpe Ratio 12m	-0.36
Alpha	-42.60
Beta	0.515
Volatility	24.31%
Current Volume	1572.4k
Average Volume 20d	1604.6k
Stop Loss	104.1 (-3%)
Signal	0.45

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (810.0m TTM) > 0 and > 6% of Revenue (6% = 426.2m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 5.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -4.38% (prev 0.68%; Δ -5.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.18 (>3.0%) and CFO 981.0m > Net Income 810.0m (YES >=105%, WARN >=100%)

Net Debt (2.71b) to EBITDA (1.45b) ratio: 1.87 <= 3.0 (WARN <= 3.5)

Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (123.7m) change vs 12m ago -1.05% (target <= -2.0% for YES)

Gross Margin 45.23% (prev 42.90%; Δ 2.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 125.6% (prev 123.3%; Δ 2.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 12.67 (EBITDA TTM 1.45b / Interest Expense TTM 88.0m) >= 6 (WARN >= 3)

Altman Z'' 1.30

(A) -0.06 = (Total Current Assets 1.61b - Total Current Liabilities 1.92b) / Total Assets 5.56b

(B) 0.08 = Retained Earnings (Balance) 432.0m / Total Assets 5.56b

(D) 0.08 = Book Value of Equity 406.0m / Total Liabilities 5.08b

Total Rating: 1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.50

1. Piotroski 8.50pt = 3.50

2. FCF Yield 4.64% = 2.32

3. FCF Margin 10.71% = 2.68

4. Debt/Equity 8.97 = -2.50

5. Debt/Ebitda 1.87 = 0.26

6. ROIC - WACC (= 28.00)% = 12.50

7. RoE 882.8% = 2.50

8. Rev. Trend 6.00% = 0.45

9. EPS Trend 55.86% = 2.79

What is the price of CLX shares?

As of November 09, 2025, the stock is trading at USD 107.36 with a total of 1,572,384 shares traded.
Over the past week, the price has changed by -4.53%, over one month by -9.97%, over three months by -13.08% and over the past year by -31.57%.

Is The Clorox a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, The Clorox (NYSE:CLX) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 74.50 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLX is around 94.81 USD . This means that CLX is currently overvalued and has a potential downside of -11.69%.

Is CLX a buy, sell or hold?

The Clorox has received a consensus analysts rating of 3.05. Therefor, it is recommend to hold CLX.

Strong Buy: 2
Buy: 2
Hold: 13
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the CLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	129.9	21%
Analysts Target Price	129.9	21%
ValueRay Target Price	104	-3.2%

CLX Fundamental Data Overview November 04, 2025

Market Cap USD = 13.69b (13.69b USD * 1.0 USD.USD)
P/E Trailing = 17.2485
P/E Forward = 19.6464
P/S = 1.9277
P/B = 46.5805
P/EG = 3.4454
Beta = 0.515
Revenue TTM = 7.10b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 91.0m USD (from shortTermDebt, last quarter)
Debt = 2.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.71b USD (from netDebt column, last quarter)
Enterprise Value = 16.41b USD (13.69b + Debt 2.88b - CCE 167.0m)
Interest Coverage Ratio = 12.67 (Ebit TTM 1.11b / Interest Expense TTM 88.0m)
FCF Yield = 4.64% (FCF TTM 761.0m / Enterprise Value 16.41b)
FCF Margin = 10.71% (FCF TTM 761.0m / Revenue TTM 7.10b)
Net Margin = 11.40% (Net Income TTM 810.0m / Revenue TTM 7.10b)
Gross Margin = 45.23% ((Revenue TTM 7.10b - Cost of Revenue TTM 3.89b) / Revenue TTM)
Gross Margin QoQ = 46.48% (prev 44.60%)
Tobins Q-Ratio = 2.95 (Enterprise Value 16.41b / Total Assets 5.56b)
Interest Expense / Debt = 0.76% (Interest Expense 22.0m / Debt 2.88b)
Taxrate = 18.05% (74.0m / 410.0m)
NOPAT = 913.8m (EBIT 1.11b * (1 - 18.05%))
Current Ratio = 0.84 (Total Current Assets 1.61b / Total Current Liabilities 1.92b)
Debt / Equity = 8.97 (Debt 2.88b / totalStockholderEquity, last quarter 321.0m)
Debt / EBITDA = 1.87 (Net Debt 2.71b / EBITDA 1.45b)
Debt / FCF = 3.57 (Net Debt 2.71b / FCF TTM 761.0m)
Total Stockholder Equity = 91.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.57% (Net Income 810.0m / Total Assets 5.56b)
RoE = 882.8% (Net Income TTM 810.0m / Total Stockholder Equity 91.8m)
RoCE = 43.29% (EBIT 1.11b / Capital Employed (Equity 91.8m + L.T.Debt 2.48b))
RoIC = 34.64% (NOPAT 913.8m / Invested Capital 2.64b)
WACC = 6.64% (E(13.69b)/V(16.57b) * Re(7.91%) + D(2.88b)/V(16.57b) * Rd(0.76%) * (1-Tc(0.18)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.35%
[DCF Debug] Terminal Value 79.79% ; FCFE base≈649.8m ; Y1≈724.3m ; Y5≈954.5m
Fair Price DCF = 136.1 (DCF Value 16.57b / Shares Outstanding 121.8m; 5y FCF grow 13.23% → 3.0% )
EPS Correlation: 55.86 | EPS CAGR: 50.65% | SUE: 1.85 | # QB: 1
Revenue Correlation: 6.00 | Revenue CAGR: 4.96% | SUE: 0.61 | # QB: 0

Additional Sources for CLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle